This is a routine compensation disclosure with no trading signal. Monitor Novo Nordisk's next earnings release or pipeline updates for material catalysts. The vesting event itself is not actionable.
Price Chart
Executive Summary
Novo Nordisk filed a routine 6-K disclosing the vesting of restricted shares under its '100th Anniversary Shares' program for ten board members and executives, including the CEO and CFO. Each recipient received 74 shares at DKK 294.30 (total ~DKK 21,778 per person) in a non-market transaction. This is a standard compensation event with no material financial or strategic implications for the company.
Key Facts
- Ten board members and executives, including CEO Maziar Mike Doustdar and CFO Karsten Munk Knudsen, received 74 shares each under a restricted share program.
- Shares vested at DKK 294.30 per share on August 5, 2026, via a non-market transaction (off-exchange).
- Total aggregate value per recipient was DKK 21,778.20 (~$3,200 USD at current rates).
- The filing is a standard Article 19 disclosure under EU Market Abuse Regulation, no change in business outlook, guidance, or financials.
Financial Impact
No material financial impact. Total vested value across all 10 recipients is approximately $32,000 USD, negligible for a $209B market cap company.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005375 |
| Document: 0001171843-26-005375-index-headers.html | 0001171843-26-005375 |
| Document: 0001171843-26-005375-index.html | 0001171843-26-005375 |
| Document: 0001171843-26-005375.txt | 0001171843-26-005375 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 6d ago | 6-K | $39.13 | awaiting T+20 | awaiting T+20 | $40.00 (+2.22%) |
Oct 26, 2026 7d ago | Court Ruling | $38.67 | awaiting T+20 | awaiting T+20 | $40.00 (+3.44%) |
Oct 19, 2026 13d ago | 6-K | $38.42 | awaiting T+20 | awaiting T+20 | $40.00 (+4.11%) |
Oct 13, 2026 19d ago | 6-K | $38.06 | awaiting T+20 | awaiting T+20 | $40.00 (+5.10%) |
Oct 6, 2026 26d ago | 6-K | $37.53 | awaiting T+20 | awaiting T+20 | $40.00 (+6.58%) |
Sep 28, 2026 4w ago | 6-K | $38.71 $38.95 | ▲ +0.61% | ▲ +0.64% | $40.00 (+3.33%) |
Sep 23, 2026 5w ago | Court Ruling | $38.62 $39.43 | ▲ +2.10% | ▲ +2.52% | $40.00 (+3.57%) |
Sep 21, 2026 5w ago | 6-K | $39.80 $38.42 | ▼ −3.47% | ▼ −2.56% | $40.00 (+0.50%) |
Sep 17, 2026 6w ago | 6-K | $43.19 $39.22 | ▼ −9.19% | ▼ −10.40% | $40.00 (−7.39%) |
Sep 15, 2026 6w ago | 6-K | $42.53 $38.06 | ▼ −10.51% | ▼ −13.23% | $40.00 (−5.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers